The targeted radionuclide therapy 177Lu-PSMA-617 has been proven effective in improving survival in men with advanced prostate cancer, according to recently published results from the VISION trial. The study, which included more than 800 men with metastatic castration-resistant prostate cancer, showed a 38% reduced risk of death and a 60% reduced risk of progression for those treated with 177Lu-PSMA-617.

Prostate cancer is the second most common cancer in men. More than 248,000 cases of prostate cancer and approximately 34,000 deaths are projected in the United States in 2021. The international phase III clinical trial focused on men with PSMA-positive prostate cancer that has progressed despite standard treatments.

Two-thirds of the men in the trial were treated with 177Lu-PSMA-617 in addition to their prescribed standard of care, while the remaining did not receive 177Lu-PSMA-617. Those treated with 177Lu-PSMA-617 saw a median progression-free survival of 8.7 months and a median overall survival of 15.3 months. Median progression-free survival and overall survival times for those who did not receive 177Lu-PSMA-617 were 3.4 months and 11.3 months, respectively.

“The results from this study are extremely promising,” says SNMMI President Alan Packard, PhD. “The treatment of metastatic castration-resistant prostate cancer with 177Lu-PSMA-617 is a prime example of how we can selectively target disease and treat it effectively with minimal side effects. We look forward this treatment becoming readily available to patients in the near future.”

177Lu-PSMA-617 is manufactured by Novartis. The company plans to seek approval for the targeted radionuclide therapy later this year.